News Releases

Return to News

Breaking News from OHC

Clinical Trials Research

Clinical Trial Insight: Gynecological Cancer Trials (Phase I Trials Begin)

OHC, Blogs, For Physicians, News Releases, 0 comments
April 16, 2014


The OHC Research Department’s complex clinical trial menu provides an opportunity for patients in and around the tri-state to participate in innovative studies which include targeted therapies.

Clinical research of gynecologic cancer has made many recent advances. Scientists continue to study the genes responsible for familial ovarian cancer. According to the American Cancer Society, this research is beginning to give us clues on how these genes normally work and how disrupting them can lead to cancer.

Research in this area has already lead to better ways in screening and detecting patients who may be at high risk for developing gynecologic cancer. As we better understand how these genes work we can begin to develop ways to prevent gynecologic cancer. New information on BRCA1 and BRCA2 gene mutations and their role in an increased risk of ovarian cancer is helping women and physicians make decisions on prevention. Studies have shown that fallopian tube cancers develop in women with BRCA gene mutations more often than physicians had previously suspected (American Cancer Society).

As research continues to grow and evolve, treatment for these cancer types will become more targeted using drugs or other substances to identify and attack cancer cells while doing little damage to normal cells. Each targeted therapy works differently but they all attack the cancer cells inner workings.

OHC is currently working to grow our gynecologic cancer research menu. We opened a Phase I trial in March 2014. OHC is participating in the REFMAL 226 (X82-CLI-101) dose expansion to evaluate the safety, tolerability, and pharmacokinetics of X-82 in patients with gynecologic cancer.

X-82 is a small molecule indolinone inhibitor of a family of type III and type V receptor tyrosine kinases (RTKs). It is a novel oral multi-kinase VEGFR/PDGFR inhibitor intended for the treatment of solid tumors. The binding of X-82 is to target receptors results in angiogenesis inhibition. It is structurally similar to sunitinib with an improved safety profile.

OHC, in partnership with the Sarah Cannon Research Institute (an internationally recognized leader in development of oncologic targeted therapies), offers multiple programs in clinical trial research, focusing within solid organ oncology diseases, including breast, colorectal/rectal, esophageal/gastric, lung (small cell and non small cell), pancreas, and other varying origins, as well as blood disorders and hematological malignancies.

Cynthia Chua, M.D.
OHC’s, Principal Investigator supporting the area of gynecological clinical research trials

To obtain further OHC Clinical Research Trial information, please contact:

S. Maria Izzo, RN
OHC Clinical Research Manager
513-751-2273 x11122

Lynnetta Hart, BS, M.Ed, CCRC
OHC Research Program Manager
513-751-2273 x27101

Teri Maraan
OHC Manager of Clinical Trial Data
513-751-2273 X12905


Leave a Reply

Your email address will not be published. Required fields are marked *